Fig. 1.
Progression-free and overall survival of 104 patients with diffuse large B-cell lymphoma according to the TNF−308A and HLA DRB1*02 status.
The initial number of patients at risk was 29 (28%) for the presence of the TNF−308A and null HLA DRB1*02 allele and 75 (72%) for the remaining patients. (A) Progression-free survival. (B) Overall survival. P denotes the log-rank test value.